Tvardi Therapeutics
TVRD
146 hedge funds and large institutions have $559M invested in Tvardi Therapeutics in 2020 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 44 increasing their positions, 29 reducing their positions, and 23 closing their positions.
57% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 23
53% more call options, than puts
Call options by funds: $10.3M | Put options by funds: $6.71M
52% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 29
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
31% more capital invested
Capital invested by funds: $426M → $559M (+$133M)
10% more funds holding
Funds holding: 133 → 146 (+13)
0.02% more ownership
Funds ownership: 1.92% → 1.94% (+0.02%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
+$7.19M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$5.12M |
| 3 |
CG
Carmignac Gestion
Paris,
France
|
+$4.27M |
| 4 |
BlackRock
New York
|
+$4.19M |
| 5 |
C
Chescapmanager
Baltimore,
Maryland
|
+$2.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$7.83M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$7.43M |
| 3 |
RCP
Rho Capital Partners
New York
|
-$6.04M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$4.27M |
| 5 |
BCM
Burrage Capital Management
Boston,
Massachusetts
|
-$3.29M |
TVRD Hedge Fund Activity: Q2 2020 in Review
146 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q2 2020, worth a combined $559M — up 31% from $426M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new TVRD positions and 23 closed out — a net gain of 13 holders — while 44 added to existing stakes and 29 trimmed.
The largest buyer was First Manhattan, adding an estimated $7.19M. The largest seller was OrbiMed, exiting entirely with an estimated $7.83M sold.
- 146 institutional investors held Tvardi Therapeutics (TVRD) as of Q2 2020, up from 133 in Q1 2020.
- Funds reported $559M of Tvardi Therapeutics stock for Q2 2020, up 31% quarter-over-quarter.
- 36 funds opened new Tvardi Therapeutics positions in Q2 2020 and 23 closed out, a net change of +13 holders.
- The largest Tvardi Therapeutics buyer in Q2 2020 was First Manhattan, an estimated $7.19M added.
- The largest Tvardi Therapeutics seller in Q2 2020 was OrbiMed, an estimated $7.83M sold.
Based on aggregated 13F filings for Q2 2020.